AKT1 and endometrial cancer: This is the first study to reveal the novel function of the dual PI3K/mTOR inhibitor in decreasing cell viability by abolishing the PI3K/Akt/mTOR/c-Myc/mtp53 positive feedback loop in endometrial cancer cell lines.